CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Quick facts
Marketed products
- Cleviprex® · Cardiovascular
Cleviprex is a dihydropyridine calcium channel blocker that selectively inhibits L-type calcium channels in vascular smooth muscle, causing vasodilation and reducing blood pressure.
Phase 3 pipeline
- Liposomal cytarabine-daunorubicin for injection · Oncology
This liposomal formulation delivers cytarabine and daunorubicin directly into leukemic cells, where both drugs inhibit DNA synthesis and induce apoptosis. - SYH2053 · Diabetes
SYH2053 is a small molecule drug that targets the SGLT2 receptor. - SYH2053/placebo injection · Cardiovascular
SYH2053 is a monoclonal antibody targeting PCSK9. - SYH2053injection · Oncology
SYH2053 is a monoclonal antibody targeting PD-1.
Phase 1 pipeline
- Amphotericin B liposome for injection · Infectious Disease
Interferes with fungal cell membrane function - SYH2061
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. portfolio CI brief
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. pipeline updates RSS
Frequently asked questions about CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
What are CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.'s marketed drugs?
Top marketed products include Cleviprex®.
What is CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.'s pipeline?
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. has 4 drugs in Phase 3, 0 in Phase 2, 2 in Phase 1. Late-stage candidates include Liposomal cytarabine-daunorubicin for injection, SYH2053, SYH2053/placebo injection, SYH2053injection.
Related
- Cleviprex® · Cardiovascular
- Sector hub: All tracked pharma companies